GPCP works closely with Weill Cornell’s Englander Institute of Precision Medicine (EIPM) to offer genomic testing to impact clinical care and advance disease research. The Englander Institute offers genomic sequencing to patients with advanced disease that lacks effective therapy. When a patient with cancer meets with the GPCP care team for an initial consultation, they will be informed about the goals of EIPM research studies, as well as potential risks and benefits of precision medicine. If patients decide to enroll in a study, they will sign a consent form giving a pathologist permission to examine tissue or genetic makeup. By enrolling in this program, patients will significantly help fuel research.
These tests help clinicians and researchers understand tumor biology, disease progression and drug resistance, and allow for the development of novel therapeutics and targeted therapies. Patients interested in the potential of precision medicine can learn more here.